Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from cardiometabolic will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs, with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,922.00 | 4.90 | 0.05% |
CAC 40 | 7,608.73 | 62.57 | 0.83% |
DAX 40 | 23,747.11 | 321.14 | 1.37% |
Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
FTSE 100 | 9,105.38 | 36.80 | 0.41% |
HKSE | 24,733.45 | 225.64 | 0.92% |
NASDAQ | 20,650.13 | 472.31 | -2.24% |
Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
NZX 50 Index | 12,684.04 | 45.36 | -0.36% |
S&P 500 | 6,238.01 | 0.00 | 0.00% |
S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
SSE Composite Index | 3,583.31 | 23.36 | 0.66% |